Wells A W, Bown N, Reid M M, Hamilton P J, Jackson G H, Taylor P R
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
J Clin Pathol. 2001 Aug;54(8):608-12. doi: 10.1136/jcp.54.8.608.
To evaluate the incidence and outcome of acute myeloid leukaemia (AML), FAB M6 (erythroleukaemia).
A demographic study in the Northern Health Region of England between 1983 and 1999.
Thirty three cases were diagnosed and registered prospectively. The overall incidence was 0.077 cases/100,000/year. There was a pronounced rise in incidence in patients aged 56 years or more: 6.6 times higher than that in younger patients. Overall survival was poor; median survival was 11 months for those aged less than 56 years, and three months for patients aged 56 years and above (p = 0.045). Acquired karyotypic abnormalities were found in 17 of 27 patients where analysis was attempted. When classified according to the criteria of the Medical Research Council AML trials, karyotype predicted survival, with a median overall survival of 14 months for those with "standard risk" cytogenetic results and two months for "poor risk" results (p = 0.005).
This study demonstrates a worse survival for patients with erythroleukaemia than that reported in some published trials of selected patients.
评估急性髓系白血病（AML）FAB M6型（红白血病）的发病率及预后。
对1983年至1999年间英格兰北部健康区域进行一项人口统计学研究。
前瞻性诊断并登记了33例病例。总体发病率为0.077例/10万/年。56岁及以上患者的发病率显著上升：比年轻患者高6.6倍。总体生存率较差；年龄小于56岁者的中位生存期为11个月，56岁及以上患者为3个月（p = 0.045）。在27例尝试进行分析的患者中，17例发现了获得性核型异常。根据医学研究委员会AML试验的标准进行分类时，核型可预测生存情况，“标准风险”细胞遗传学结果者的中位总生存期为14个月，“高风险”结果者为2个月（p = 0.005）。
本研究表明，红白血病患者的生存情况比一些已发表的特定患者试验报告的情况更差。
